IS2749B - Ný tegund af lyfjablöndu - Google Patents

Ný tegund af lyfjablöndu

Info

Publication number
IS2749B
IS2749B IS5361A IS5361A IS2749B IS 2749 B IS2749 B IS 2749B IS 5361 A IS5361 A IS 5361A IS 5361 A IS5361 A IS 5361A IS 2749 B IS2749 B IS 2749B
Authority
IS
Iceland
Prior art keywords
formulation
new type
pregabalin
gabapentin
useful
Prior art date
Application number
IS5361A
Other languages
English (en)
Other versions
IS5361A (is
Inventor
Taylor Charles Price Jr
Antonio Guglietta
Ren Jiayuan
William Patrick Watson
Laurent Diop
Maria Chovet
Lionel Bueno
Hillary J Little
Michael Francis Rafferty
Original Assignee
Warner Lambert Co
Regents For The University Of Oklahoma Board Of
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=27369092&utm_source=***_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=IS2749(B) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Warner Lambert Co, Regents For The University Of Oklahoma Board Of filed Critical Warner Lambert Co
Publication of IS5361A publication Critical patent/IS5361A/is
Publication of IS2749B publication Critical patent/IS2749B/is

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
    • A61K31/42—Oxazoles
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/185—Acids; Anhydrides, halides or salts thereof, e.g. sulfur acids, imidic, hydrazonic or hydroximic acids
    • A61K31/19—Carboxylic acids, e.g. valproic acid
    • A61K31/195—Carboxylic acids, e.g. valproic acid having an amino group
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/185—Acids; Anhydrides, halides or salts thereof, e.g. sulfur acids, imidic, hydrazonic or hydroximic acids
    • A61K31/19—Carboxylic acids, e.g. valproic acid
    • A61K31/195—Carboxylic acids, e.g. valproic acid having an amino group
    • A61K31/197—Carboxylic acids, e.g. valproic acid having an amino group the amino and the carboxyl groups being attached to the same acyclic carbon chain, e.g. gamma-aminobutyric acid [GABA], beta-alanine, epsilon-aminocaproic acid or pantothenic acid
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/40—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/40—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil
    • A61K31/403—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil condensed with carbocyclic rings, e.g. carbazole
    • A61K31/404—Indoles, e.g. pindolol
    • A61K31/405—Indole-alkanecarboxylic acids; Derivatives thereof, e.g. tryptophan, indomethacin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/54—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with at least one nitrogen and one sulfur as the ring hetero atoms, e.g. sulthiame
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/60—Salicylic acid; Derivatives thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/04—Drugs for disorders of the alimentary tract or the digestive system for ulcers, gastritis or reflux esophagitis, e.g. antacids, inhibitors of acid secretion, mucosal protectants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/30—Drugs for disorders of the nervous system for treating abuse or dependence
    • A61P25/32—Alcohol-abuse
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Chemical & Material Sciences (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Epidemiology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Organic Chemistry (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Addiction (AREA)
  • Biomedical Technology (AREA)
  • Psychiatry (AREA)
  • Rheumatology (AREA)
  • Neurology (AREA)
  • Neurosurgery (AREA)
  • Pain & Pain Management (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Medicines Containing Plant Substances (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Indole Compounds (AREA)
IS5361A 1997-08-20 2000-01-25 Ný tegund af lyfjablöndu IS2749B (is)

Applications Claiming Priority (4)

Application Number Priority Date Filing Date Title
US5675397P 1997-08-20 1997-08-20
US7479498P 1998-02-16 1998-02-16
US8293698P 1998-04-24 1998-04-24
PCT/US1998/017082 WO1999008671A1 (en) 1997-08-20 1998-08-18 Gaba analogs to prevent and treat gastrointestinal damage

Publications (2)

Publication Number Publication Date
IS5361A IS5361A (is) 2000-01-25
IS2749B true IS2749B (is) 2011-08-15

Family

ID=27369092

Family Applications (1)

Application Number Title Priority Date Filing Date
IS5361A IS2749B (is) 1997-08-20 2000-01-25 Ný tegund af lyfjablöndu

Country Status (25)

Country Link
US (2) US6242488B1 (is)
EP (1) EP1009399B1 (is)
JP (1) JP4681116B2 (is)
KR (2) KR100609359B1 (is)
AT (1) ATE461698T1 (is)
AU (2) AU8668598A (is)
BR (1) BR9812133A (is)
CA (1) CA2297163C (is)
CO (1) CO4960645A1 (is)
CY (1) CY1109981T1 (is)
DE (1) DE69841574D1 (is)
DK (1) DK1009399T3 (is)
ES (1) ES2341154T3 (is)
HU (1) HUP0004551A3 (is)
IL (1) IL134164A (is)
IS (1) IS2749B (is)
MY (1) MY155223A (is)
NO (1) NO327983B1 (is)
NZ (1) NZ502729A (is)
PE (1) PE107299A1 (is)
PL (1) PL194125B1 (is)
PT (1) PT1009399E (is)
TW (2) TW570794B (is)
UY (1) UY25148A1 (is)
WO (2) WO1999008670A1 (is)

Families Citing this family (64)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DK0934061T6 (en) 1996-07-24 2015-01-26 Warner Lambert Co Isobutylgaba and its derivatives for the treatment of pain
NZ502671A (en) 1997-09-08 2003-01-31 Warner Lambert Co Combination of an analgesic with anti-epileptic properties and a NSAID
EP1031350A1 (en) * 1999-02-23 2000-08-30 Warner-Lambert Company Use of a gabapentin-analog for the manufacture of a medicament for preventing and treating visceral pain
JP2002538221A (ja) * 1999-03-10 2002-11-12 ワーナー−ランバート・カンパニー 抗てんかん作用を有する化合物を包含する鎮痛組成物およびその使用方法
US6992109B1 (en) * 1999-04-08 2006-01-31 Segal Catherine A Method for the treatment of incontinence
DE60022333T2 (de) * 1999-04-09 2006-07-06 Euro-Celtique S.A. Natrium kanalblocker zusammensetzungen und deren verwendung
EP1840117A1 (en) * 1999-06-10 2007-10-03 Warner-Lambert Company LLC Mono- and disubstituted 3-propyl gamma-aminobutyric acids
ATE359068T1 (de) 1999-07-22 2007-05-15 Univ Rochester Methode zur behandlung der symptome hormoneller veränderungen, einschliesslich hitzewallungen
FR2801217B1 (fr) * 1999-11-24 2002-12-06 Aventis Pharma Sa Association de riluzole et de gabapentine et son utilisation comme medicament
EP1294854A2 (en) * 2000-05-16 2003-03-26 Warner-Lambert Company Cell line for the expression of an alpha2-delta2 calcium channel subunit
AU2002211863A1 (en) 2000-10-06 2002-04-15 Xenoport, Inc. Bile-acid derived compounds for providing sustained systemic concentrations of drugs after oral administration
EP1361847A2 (en) 2000-10-06 2003-11-19 Xenoport, Inc. Bile-acid conjugates for providing sustained systemic concentrations of drugs
EP1226820A1 (en) * 2001-01-26 2002-07-31 Warner-Lambert Company Use of bicyclic amino acids for preventing and treating visceral pain and gastrointestinal disorders
US7186855B2 (en) 2001-06-11 2007-03-06 Xenoport, Inc. Prodrugs of GABA analogs, compositions and uses thereof
US6818787B2 (en) 2001-06-11 2004-11-16 Xenoport, Inc. Prodrugs of GABA analogs, compositions and uses thereof
EP2085087A1 (en) 2001-06-11 2009-08-05 Xenoport, Inc. Prodrugs of gaba analogs, compositions and uses thereof
AU2002345638A1 (en) 2001-06-11 2002-12-23 Xenoport, Inc. Amino acid conjugates providing for sustained systemic concentrations of gaba analogues
US8048917B2 (en) 2005-04-06 2011-11-01 Xenoport, Inc. Prodrugs of GABA analogs, compositions and uses thereof
BRPI0212298B8 (pt) 2001-09-03 2021-05-25 Newron Pharm Spa composição farmacêutica compreendendo gabapentina ou um análogo da mesma e (alfa)-aminoamida e seu uso analgésico
TWI312285B (en) 2001-10-25 2009-07-21 Depomed Inc Methods of treatment using a gastric retained gabapentin dosage
US20060159743A1 (en) * 2001-10-25 2006-07-20 Depomed, Inc. Methods of treating non-nociceptive pain states with gastric retentive gabapentin
US20070184104A1 (en) * 2001-10-25 2007-08-09 Depomed, Inc. Gastric retentive gabapentin dosage forms and methods for using same
US7612112B2 (en) 2001-10-25 2009-11-03 Depomed, Inc. Methods of treatment using a gastric retained gabapentin dosage
WO2003077902A1 (en) 2002-02-19 2003-09-25 Xenoport, Inc. Methods for synthesis of prodrugs from 1-acyl-alkyl derivatives and compositions thereof
AU2003246864A1 (en) * 2002-02-22 2003-09-09 Warner-Lambert Company Llc Combinations of an alpha-2-delta ligand with a selective inhibitor of cyclooxygenase-2
US7026351B2 (en) 2002-03-20 2006-04-11 Xenoport, Inc. Cyclic 1-(acyloxy)-alkyl prodrugs of GABA analogs, compositions and uses thereof
US7183259B2 (en) 2002-05-17 2007-02-27 Xenoport Amino acid conjugates providing for sustained systemic concentrations of GABA analogues
EP1549302A1 (en) * 2002-07-10 2005-07-06 Warner-Lambert Company LLC Gastrointestinal compositions comprising gaba derivatives
US7025745B2 (en) * 2002-10-07 2006-04-11 Advanced Cardiovascular Systems, Inc. Method of making a catheter balloon using a tapered mandrel
US7473432B2 (en) * 2002-10-11 2009-01-06 Idea Ag NSAID formulations, based on highly adaptable aggregates, for improved transport through barriers and topical drug delivery
US7060727B2 (en) 2002-12-11 2006-06-13 Xenoport, Inc. Prodrugs of fused GABA analogs, pharmaceutical compositions and uses thereof
MXPA05006209A (es) * 2002-12-13 2005-08-19 Warner Lambert Co Pregabalina y sus derivados para el tratamiento de fibromialgia y otros trastornos relacionados.
ES2341240T3 (es) * 2002-12-13 2010-06-17 Warner-Lambert Company Llc Ligando alfa-2-delta para tratar los sintomas del tracto urinario inferior.
CA2451267A1 (en) * 2002-12-13 2004-06-13 Warner-Lambert Company Llc Pharmaceutical uses for alpha2delta ligands
BRPI0408110A (pt) 2003-03-07 2006-03-01 Warner Lambert Co derivados de beta-aminoácido substituìdos com tetrazol e oxadiazolona
WO2004084881A1 (en) * 2003-03-21 2004-10-07 Dynogen Pharmaceuticals, Inc. METHODS FOR TREATING FUNCTIONAL BOWEL DISORDERS USING α2δ SUBUNIT CALCIUM CHANNEL MODULATORS WITH SMOOTH MUSCLE MODULATORS
US20050043407A1 (en) * 2003-08-22 2005-02-24 Pfizer Inc Pharmaceutical composition for the prevention and treatment of addiction in a mammal
JP2007505149A (ja) 2003-09-11 2007-03-08 ゼノポート，インコーポレイティド ギャバ類似体のプロドラッグを用いる尿失禁の治療および／あるいは予防
CN1871021B (zh) 2003-09-17 2010-07-28 什诺波特有限公司 用gaba类似物的前药治疗或预防多动腿综合征
US8026279B2 (en) 2003-10-14 2011-09-27 Xenoport, Inc. Crystalline form of γ-aminobutyric acid analog
PT1691811E (pt) 2003-12-11 2014-10-30 Sunovion Pharmaceuticals Inc Combinação de um sedativo e de um modulador de neurotransmissores e métodos para melhorar a qualidade do sono e tratamento da depressão
ATE371496T1 (de) * 2004-03-12 2007-09-15 Warner Lambert Co C1-symmetrische bisphosphinliganden und deren verwendung bei der asymmetrischen synthese von pregabalin
DE602005009161D1 (de) * 2004-04-01 2008-10-02 Warner Lambert Co Herstellung von p-chirogenen phospholanen und deren verwendung in der asymmetrischen synthese
AU2005256945B2 (en) * 2004-06-21 2008-11-13 Upjohn Us 1 Llc Preparation of pregabalin and related compounds
RS51411B (en) * 2004-09-10 2011-02-28 Newron Pharmaceuticals S.P.A. USE (R) - (HALOBENZYLOXY) BENZYLAMINO-PROPANAMIDE AS SELECTIVE MODULATORS OF SODIUM AND / OR CALCIUM CHANNELS
RU2440112C2 (ru) 2004-11-04 2012-01-20 Ксенопорт, Инк. Пероральная дозированная форма габапентина замедленного высвобождения
PT1963280E (pt) * 2005-12-22 2016-02-02 Newron Pharm Spa Derivados de 2-feniletilamino como cálcio e/ou moduladores do canal de sódio
US20090176882A1 (en) * 2008-12-09 2009-07-09 Depomed, Inc. Gastric retentive gabapentin dosage forms and methods for using same
CA2672044A1 (en) * 2006-12-08 2008-06-19 Xenoport, Inc. Use of prodrugs of gaba analogs for treating diseases
CA2703472A1 (en) * 2007-10-26 2009-04-30 The Scripps Research Institute Methods for treating substance dependence
US7868043B2 (en) 2008-01-25 2011-01-11 Xenoport, Inc. Mesophasic forms of (3S)-aminomethyl-5-methyl-hexanoic acid prodrugs and methods of use
TWI369202B (en) 2008-01-25 2012-08-01 Xenoport Inc Enantiomerically resolving acyloxyalkyl thiocarbonates used in synthesizing acyloxyalkyl carbamate prodrugs
EP2250148B1 (en) 2008-01-25 2016-08-17 XenoPort, Inc. Crystalline form of calcium-salts of (3s)-aminomethyl-5-methyl-hexanoic acids and methods of use
SG176464A1 (en) 2008-05-09 2011-12-29 Agency Science Tech & Res Diagnosis and treatment of kawasaki disease
US8268887B2 (en) 2008-10-08 2012-09-18 Feng Xu Drug conjugates and methods of use thereof
AU2010270976B2 (en) * 2009-06-22 2014-03-20 Pf Consumer Healthcare 1 Llc Sodium ibuprofen tablets and methods of manufacturing pharmaceutical compositions including sodium ibuprofen
WO2011141923A2 (en) 2010-05-14 2011-11-17 Lupin Limited Improved synthesis of optically pure (s) - 3-cyano-5-methyl-hexanoic acid alkyl ester, an intermediate of (s)- pregabalin
WO2012059797A1 (en) 2010-11-04 2012-05-10 Lupin Limited Process for synthesis of (s) - pregabalin
US9066853B2 (en) 2013-01-15 2015-06-30 Warsaw Orthopedic, Inc. Clonidine compounds in a biodegradable fiber
US10130715B2 (en) 2013-01-28 2018-11-20 Hector L. Lopez Methods of improving tolerability, pharmacodynamics, and efficacy of β-alanine and use therefor
CN105997970A (zh) * 2015-12-16 2016-10-12 南昌大学 γ-氨基丁酸在制备胃粘膜保护剂中的应用
US10052296B2 (en) 2016-04-07 2018-08-21 Nevakar Inc. Formulations for treating pain
WO2019070641A1 (en) 2017-10-03 2019-04-11 Nevakar Inc. COMBINATIONS OF ACETAMINOPHENE-PRÉGABALINE AND METHODS OF TREATING PAIN
AU2019271799B2 (en) 2018-05-14 2023-10-12 Xgene Pharmaceutical Inc. Crystalline forms of 1-(acyloxy)-alkyl carbamate drug conjugates of naproxen and pregabalin

Family Cites Families (23)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
BE634102A (is)
DE1966802C3 (de) 1969-12-20 1975-11-06 Desitin-Werk, Carl Klinke Gmbh, 2000 Hamburg 5,5-Diphenylhydantoin-N hoch 3 -carbonsäureester
JPS54110334A (en) 1978-02-16 1979-08-29 Fuji Chem Ind Co Ltd Novel compounded anodyne and antiiinflammatory agent
US4158581A (en) 1978-04-14 1979-06-19 Westinghouse Electric Corp. Method of making magnetic component for direct current apparatus
JPS61221121A (ja) 1985-03-27 1986-10-01 Nitto Electric Ind Co Ltd テ−プ製剤
US4694010A (en) 1985-08-16 1987-09-15 New York University Anticonvulsant compositions and method
AU2929489A (en) 1987-12-22 1989-07-19 John W. FERKANY Dextrorphan potentiator for anticonvulsant composition and method
WO1992009560A1 (en) 1990-11-27 1992-06-11 Northwestern University Gaba and l-glutamic acid analogs for antiseizure treatment
GB9108362D0 (en) 1991-04-18 1991-06-05 Radoslavov Alexander A pharmaceutical composition suitable for alleviation of headaches,migraine and other painful conditions
RU2140901C1 (ru) * 1992-05-20 1999-11-10 Нортвестерн Юниверсити АНАЛОГИ γ-АМИНОМАСЛЯНОЙ КИСЛОТЫ, СПОСОБ ИХ ПОЛУЧЕНИЯ, СПОСОБ ЛЕЧЕНИЯ И ФАРМАЦЕВТИЧЕСКАЯ КОМПОЗИЦИЯ
US5234929A (en) 1992-07-20 1993-08-10 William Chelen Method of treating motion sickness with anticonvulsants and antitussive agents
JPH06100468A (ja) 1992-09-25 1994-04-12 Kibun Food Chemifa Co Ltd 徐放性組成物
US5321012A (en) 1993-01-28 1994-06-14 Virginia Commonwealth University Medical College Inhibiting the development of tolerance to and/or dependence on a narcotic addictive substance
JPH06227969A (ja) 1993-02-02 1994-08-16 Masayasu Sugihara 薬品の腸溶性改善方法およびそれにより得られた薬品組成物
US5420270A (en) 1993-10-07 1995-05-30 G. D. Searle & Co. Aryl substituted dibenzoxazepine compounds, pharmaceutical compositions and methods of use
US5352638A (en) 1994-02-22 1994-10-04 Corning Incorporated Nickel aluminosilicate glass-ceramics
PL319029A1 (en) 1994-09-02 1997-07-21 Univ Virginia Commonwealth Pain relieving preparation containing non-nercotic analgesic compound and analgesic action enhancing compound
GB9420784D0 (en) * 1994-10-14 1994-11-30 Glaxo Group Ltd Medicaments
CN1046199C (zh) 1994-12-13 1999-11-10 凌吉安 复方消炎止痛霜剂
CA2264182A1 (en) * 1996-08-23 1998-02-26 Algos Pharmaceutical Corporation Anticonvulsant containing composition for treating neuropathic pain
SE9603408D0 (sv) * 1996-09-18 1996-09-18 Astra Ab Medical use
BR9712651A (pt) * 1996-10-23 1999-10-26 Warner Lambert Co ‡cidos gama-aminobutìricos substituìdos com agentes farmacêuticos.
US6127418A (en) * 1997-08-20 2000-10-03 Warner-Lambert Company GABA analogs to prevent and treat gastrointestinal damage

Also Published As

Publication number Publication date
HUP0004551A2 (hu) 2001-05-28
KR20050116168A (ko) 2005-12-09
BR9812133A (pt) 2000-07-18
DE69841574D1 (de) 2010-05-06
NO20000786L (no) 2000-02-17
JP2001515033A (ja) 2001-09-18
IL134164A0 (en) 2001-04-30
MY155223A (en) 2015-09-30
US6242488B1 (en) 2001-06-05
TW200412938A (en) 2004-08-01
CY1109981T1 (el) 2014-09-10
PT1009399E (pt) 2010-05-21
KR100609359B1 (ko) 2006-08-04
PL338705A1 (en) 2000-11-20
US20010014698A1 (en) 2001-08-16
AU9293098A (en) 1999-03-08
CA2297163C (en) 2001-11-20
UY25148A1 (es) 1999-01-26
WO1999008670A1 (en) 1999-02-25
JP4681116B2 (ja) 2011-05-11
NO20000786D0 (no) 2000-02-17
CA2297163A1 (en) 1999-02-25
IS5361A (is) 2000-01-25
TW570794B (en) 2004-01-11
NO327983B1 (no) 2009-11-02
EP1009399A1 (en) 2000-06-21
US6426368B2 (en) 2002-07-30
WO1999008671A1 (en) 1999-02-25
DK1009399T3 (da) 2010-05-31
NZ502729A (en) 2002-10-25
KR20010023084A (ko) 2001-03-26
TWI251485B (en) 2006-03-21
EP1009399B1 (en) 2010-03-24
IL134164A (en) 2005-05-17
ES2341154T3 (es) 2010-06-15
ATE461698T1 (de) 2010-04-15
PL194125B1 (pl) 2007-04-30
HUP0004551A3 (en) 2002-11-28
PE107299A1 (es) 1999-12-19
CO4960645A1 (es) 2000-09-25
AU8668598A (en) 1999-03-08

Similar Documents

Publication Publication Date Title
IS2749B (is) Ný tegund af lyfjablöndu
NO2008018I2 (no) (3S)-3-(Aminometyl)-5-metylheksansyre (Pregabalin)eller et farmasøytisk akseptabelt salt derav
HK1070305A1 (en) Pharmaceutical composition comprising gabapentin or an analogue thereof and an sg(a)-aminoamide and its analgesic use
DK0840606T3 (da) Små di- og trivalente molekyler som selectininhibitorer
NO974069L (no) Orale farmasöytiske doseringsformer omfattende en protonpumpeinhibitor og et NSAID
DK0867178T3 (da) Non-allosteriske GABA A agonister til behandling af søvnforstyrrelser
DK0994704T3 (da) Anvendelse af GABA-analoger såsom gabapentin i fremstillingen af et medikament til behandling af inflammatoriske sygdomme
NO983530D0 (no) Dihydrobenzofuran og relaterte forbindelser anvendelig som anti-inflammatoriske midler
ES2170143T3 (es) Composiciones que comprenden halofantrina en una forma especial.
DK1023034T3 (da) Kosmetiske formuleringer til forebyggelse mod og behandling af hårtab
NO982229D0 (no) Svovelholdige di-tert-butylfenol-forbindelser anvendbare som antiinflammatoriske midler
EP0974351A3 (en) Medicament for preventing and treating gastrointestinal damage
NO20010116D0 (no) Farmasöytisk preparat inneholdende GABA-analoger og et antiviralt middel for å behandle helvetesild
DK1414496T3 (da) Farmaceutisk sammensætning indeholdende en kombination af PPAR-alpha, pravastatin og mindst en polyglycoliseret glycerid
MX9204528A (es) 0etodo para tratar el sindrome premenstrual mediante administracion de un inhibidor de la enzima de conversion de angiotensina.
ATE232724T1 (de) Inhibitor von stickstoffmonoxid (no) synthase zur verhütung von typ ii diabetes
ATE305778T1 (de) Behandlung von nierenkolik mit gaba-analogen
ECSP003471A (es) Inhibidor de metaloproteasa acido aromatico sulfohidroxamico
AU2002317548A1 (en) GABA analogs to prevent and treat gastrointestinal damage
ECSP982631A (es) Metodo para prevenir y tratar lesiones gastrointestinales